温和灸治疗肾阳虚型绝经后骨质疏松症的临床及相关实验研究
|
摘要
目的：
1通过随机设计的临床研究,观察温和灸对肾阳虚型绝经后骨质疏松症骨转换指标、临床骨痛及肾阳虚证候的影响,探讨其防治骨质疏松症临床效果及作用机制。
2通过实验研究来检测艾灸血清对骨质疏松症成骨细胞增殖率及凋亡情况,从细胞分子水平探讨其治疗骨质疏松症的作用机理。
方法：
1临床实验：运用温和灸疗法治疗肾阳虚型绝经后骨质疏松症,共入选研究病例90例,随机分为三组,每组各30例,研究结束后剔除不符合研究要求及脱落病例,共纳入统计病例87例,分别为：钙剂组28例,中成药组30例,温和灸组29例。钙剂组患者予以口服钙尔奇碳酸钙D3片,1片/次,1次/日。中成药组患者在钙剂组的治疗基础上加服仙灵骨葆胶囊,每次3粒,每日两次,温和灸组在钙剂组的治疗基础上循经取穴行温和灸疗法,隔日一次,取穴为3个主穴+3个配穴,主穴如下：脾俞、胃俞、肾俞。配穴选用命门、腰阳关、至阳。三组均连续治疗三个月,观察治疗前后肾阳虚证侯的变化及临床骨痛改善情况、骨密度、体表红外热图皮温的改变,并按中医临床疗效评定标准评价其疗效,空腹抽血检测治疗前后患者的骨形成相关指标：血清骨钙素(BGP)、血清骨碱性磷酸酶(BALP)。骨吸收相关指标抗酒石酸酸性磷酸酶5b(TRACP-5b)、骨保护素(OPG)。骨矿化指标血钙(Ca)、血磷(P)。治疗前后各指标比较组内采用配对样本t检验,组间差异用方差分析,行LSD、SNK法进行统计分析。
2体外培养细胞实验：通过观察大鼠艾灸血清对成骨细胞增殖与凋亡的影响,来探讨温和灸治疗骨质疏松症的细胞生物学机理。取10只出生24小时的新生SD大鼠无菌取颅盖顶骨,用单纯胶原酶消化法行成骨细胞培养,制成DMEM培养液重悬细胞,吹打均匀后接种到多个37℃、5%CO2饱和湿度的培养瓶中进行培养,进行成骨细胞HE染色观察及ALP染色鉴定,取二代细胞进行实验。将6月龄SD雌性大鼠随机分成2组：艾灸血清组、空白血清组,每组10只,艾灸血清组经用陈艾绒制成的艾条在大鼠背俞穴(脾俞、胃俞、肾俞、命门、腰阳关、至阳)行温和灸法,每天一次,每穴10分钟,连续21天,空白血清组大鼠除不作艾灸治疗外,余处理同艾灸血清组。制备艾灸血清和空白血清,同组血清混合后过滤除菌,56℃、30分钟水浴灭活,无菌冻存管分装、标记后-30℃冻存备用。取艾灸血清加入DMEM培养基中,制成含10%艾灸血清的培养液,同样取空白血清加入DMEM培养基中,制成含10%空白血清的培养液。将培养液分为空白对照组(含10%FBS、DMEM)、血清对照组(含10%空白血清、DMEM)和艾灸血清组(含10%艾灸血清、DMEM)三组进行培养,分别在24小时、48小时培养结束后,用MTT法检测成骨细胞增殖活性。按不同培养液条件分为空白对照组(含DMEM、10%FBS)、凋亡诱导组(DMEM.10%FBS、40ng/mlTNF-α),血清对照组(DMEM、10%空白血清、40ng/mlTNF-α)和艾灸血清组(DMEM、10%艾灸血清、40ng/mlTNF-α)四组,继续二代细胞培养,培养在48小时后完成,做HE、DAPI荧光染色,通过荧光倒置显微镜下检测成骨细胞凋亡情况。
结果：
1临床研究表明
肾阳虚证候积分测定结果：
治疗前后比较,钙剂组肾阳虚证候总积分比较无明显差异(P=0.676>0.05),中成药组畏寒肢冷证候积分无明显差异(P=0.083>0.05),余指标均有明显差异(P<0.01),其中以夜尿频多及疲乏无力证候改变为明显(P=0.001及P=0.003),温和灸组以畏寒肢冷、大便溏薄积分降低为明显(P=0.003及P=0.001),余证候积分P<0.05。治疗后组间方差分析两两比较,中成药组、温和灸与钙剂组在腰背疼痛及肾阳虚总积分改善方面有明显差异(P<0.05),温和灸与中成药组比较仅畏寒肢冷证候指标有显著差异(P=0.002<0.01),余证候指标相比较无明显差异(P>0.05)。
临床VAS测定结果：
治疗前后比较,钙剂组对于患者主观腰背疼痛症状无好转,VAS积分无明显改变,而中成药组及温和灸组均有明显好转(P=0.000<0.01)。治疗后三组组间比较,钙剂组VAS积分变化较小,中成药组与温和灸组相比,VAS积分下降幅度较大(P=0.015<0.05)。
红外热像皮温值测定结果：
结果显示,各组治疗前比较局部温度无明显差异,组内治疗前后比较,温和灸组局部温度明显升高(P=0.001<0.01),其他两组无明显差异。组间比较,温和灸组患者较其他两组患者局部温度增高,具有显著差异性(与钙剂组比较P=001,与中成药组比较P=0.014),钙剂组与中成药组无明显差异(P=0.389>0.05)。
中医临床疗效测定结果：
温和灸组临床显效占31.0%,总有效率86.2%。中成药组显效占33%,总有效率86.7%,温和灸组和中成药组疗效无明显差异,但均明显优于钙剂组(P=0.007<0.01)。
骨密度测定结果：骨密度各组间治疗后比较,均无显著差异。
骨转换指标的测定结果：
三组治疗前比较,各指标无明显差异,具有可比性(P>0.05),BGP组内比较,中药组及温和灸组有显著差异(P=0.000<0.01),钙剂组无明显差异。BGP组间比较,温和灸组较钙剂组显著增加(P=0.004<0.01),较中成药组明显无明显改变(P=0.075>0.05)。
BALP组内比较,钙剂组治疗前后无明显差异,中成药组BALP有所增加(P=0.001<0.01),温和灸增高的幅度略大(P=0.000<0.01)。组间与钙剂组相比较,均存在一定的差异性(P<0.01>0.05),中成药组和温和灸组增高值相比较无明显差异,都在正常范围(P=0.306)。
三组TRACP5b均有下降,钙剂组治疗前后比较无差异,中成药组及温和灸治疗前后相比较,具有显著差异(P<0.01),三组治疗后比较,钙剂组与中成药组比较存在显著差异性(P=0.005<0.01),与温和灸组比较有差异(P=0.013<0.05),中成药组与温和灸组比较无明显差异(P=0.775>0.05)。
OPG组内比较,中成药组存在显著差异(P=0.001<0.01),温和灸存在显著差异(P=0.002<0.01)。但治疗后组间比较,温和灸组与钙剂组相比,有一定程度的下降(P=0.044<0.05),中成药组与钙剂组比较有差异(P=0.046<0.05)。
三组治疗前后及各组间比较,血清钙、磷水平无明显差异(P>0.05)。
2实验研究表明,空白对照组成骨细胞凋亡率及凋亡细胞均值较其他三组少(P=0.000),艾灸血清组成骨细胞凋亡率、凋亡细胞均值与凋亡诱导组及血清对照组比较,有明显差异(P<0.05),血清对照组与凋亡诱导组比较无明显差异(P>0.05)。三组在24小时时段成骨细胞增殖OD570值无明显差异(P>0.05),在48小时后各组OD570均有明显增加,艾灸血清组增殖幅度较大,与空白对照组及血清对照组比较,有显著差异(P<0.05),血清对照组与空白对照组比较无明显差异(P>0.05)。在不同时段比较,空白对照组和血清对照组OD570值均增加,但组内比较尚无明显差异(P>0.05),艾灸血清组不同时段组内比较,成骨细胞OD570值有明显增加(P<0.01)。
结论：
1温和灸能明显改善肾阳虚绝经后骨质疏松症患者临床症状,缓解骨质疏松症骨痛,并优于其他治疗组。
2温和灸可明显提高肾阳虚型骨质疏松症腰部疼痛部位及周围的红外热像皮温值,有效改善肾阳虚证候。
3温和灸可提高骨形成相关指标水平,降低骨吸收相关指标,降低肾阳虚型PMOP的骨转换。
4艾灸血清能促进成骨细胞增殖,可减少TNF-α诱导的成骨细胞凋亡数量。
Objective
1Through a randomized clinical study designs, to observe the effect of Bone turnover markers, Clinical pain and Kidney yang deficiency syndrome on postmenopausal osteoporosis. to analysis the prevention of osteoporosis clinical efficacy and mechanism of action.
2Through the experimental research to detect the effect of moxibustion serum on osteoporosis osteoblast proliferation and apoptosis, From the cellular and molecular level to investigate its role in the treatment of osteoporosis mechanism.
Methods
1Clinieal study:A total of90patients with postmenopausal osteoporosis in kidney yang deficiency were assigned, and randomly divided into3groups,30cases in each group, the end of the study does not meet the research requirements and elimination after shedding case, were included in the statistical case87examples, respectively:28cases in the Calcium agent group,30cases in the Proprietary Chinese medicine group and29cases in the mild moxibustion group. Patiets in the Calcium agent group were treated by1Calcium carbonate tablets D3once daily, Patiets in the the Proprietary Chinese medicine group were treated by3Xianlinggubao capsules twice daily and1Calcium carbonate tablets D3once daily. Patiets in the mild moxibustion group were treated by mild moxibustion on the The main points as Pishu point, WeiShu point, ShenShu point and acupoints as Mingmen acupoint acupoints, YaoYangGuan acupoint, ZhiYang acupoint Once every other day and1Calcium carbonate tablets D once daily. All the patients were treated for three months. To Observe the change of Kidney yang deficiency syndrome, Clinical pain, Bone mineral density and Body surface skin temperature of infrared thermograph. According to TCM clinic curative effect evaluation of its curative effect. Meanwhile to determinate patients with bone formation index such as Osteocalcin(BGP), serum bone alkaline phosphatase(BALP), bone resorption index such as tartrate-resistant acid phosphatase5b (TRACP-5b), osteoprotegerin (OPG),bone mineralization indicators serum calcium(Ca), phosphorus(P). Comparison of indexes before and after treatment in group was used with paired sample t test, the differences between groups was used with analysis of variance, LSD, SNK method for statistical analysis, with P<0.05was considered statistically significant criteria.
2In vitro experiment:Through the observation of moxibustion serum on rat osteoblast proliferation and apoptosis, on mild-warm moxibustion for treatment of osteoporosis in cell biological mechanism.10born only24hours of neonatal SD rat calvarial bone aseptic were taken. DMEM medium heavy suspension cells came from Using pure collagenase digestion method line of osteoblasts culture, after All culture osteoblasts were inoculated into a plurality of37℃,5%CO2saturated humidity flask uniformed by Wind and percussion. HE staining and ALP staining identification were Conducted, experiments were using of the two generation cell. June old female SD rats were randomly divided into2groups, Each group of10. The rats of moxibustion serum group were treated with gentle moxibustion by moxa cone made by old argy wormwood leaf in rat Back-shu points once a day, each of10minutes for21days, To preparated moxibustion serum and blank serum. The same group of serum after mixing, filtration,56degrees,30minutes bath inactivation aseptic packaging, freezing tube, mark-30℃of cryopreserved standby. Using moxibustion serum added in DMEM medium containing10%, made of moxibustion serum medium, also take blank control group rats serum made with10%serum controls medium. The culture fluid is divided into the blank control group (10%FBS, DMEM), Serum control group (including10%blank serum, DMEM) and moxibustion serum group (including10%moxibustion serum, DMEM) in three groups were cultured respectively, in24hours,48hours after the cultivation,Use MTT method to detect the activity of osteoblast proliferation. According to different culture conditions were divided into control group(DMEM,10%FBS), Apoptosis induced by group (DMEM,10%FBS,40ng/ml TNF alpha), The control group, serum (DMEM,10%blank serum,40ng/ml TNF alpha)and moxibustion serum group (DMEM,10%,40ng/ml TNF moxibustion serum alpha) in four groups, continue to the two generation in cell culture, culture at48hours after completion, do DAPI fluorescence staining, Through an inverted fluorescence microscope osteoblast apoptosis.
Result
1In clinical studies have shown as follows:
Kidney yang deficiency syndrome integral determination results:
Calcium group of kidney-yang deficiency syndrome total no difference (P=0.676>0.05), Chinese medicine group of aversion to cold syndrome scores showed no significant difference(P=0.083>0.05), More than indicators have obvious differences (P<0.01), with nocturia and fatigue without evidence of climate change (P=0.001and P=0.003), Mild moxibustion group with aversion to cold, thin integral stool pond is reduced to significantly(P=0.003andP=0.001), P<0.05points more than syndrome. After treatment between group variance analysis comparison of two two, Chinese medicine group, mild moxibustion group and calcium in low back pain and kidney yang deficiency total integral improvement have obvious difference(P<0.05), Mild moxibustion and medicine group comparison only aversion to cold syndrome indices are significantly different(P=0.002<0.01), Other syndromes indices compared with no significant difference (P>0.05). Clinical result of measurement of VAS:
Comparison before and after treatment, calcium group for low back pain patients with subjective symptoms do not improve, VAS integral has no obvious change, and Chinese patent medicine group and mild moxibustion group were improved significantly(P=0<0.01). Between group after treatment between the three groups, calcium group VAS integral small changes, Chinese medicine group and mild moxibustion group compared with the VAS integral, a larger decrease(P=0.015<0.05).
Infrared thermography of skin temperature measurement results:
The results showed, each group before treatment comparison of local temperature had no significant differences within the group, after treatment, mild moxibustion group of local temperature increased significantly (P=0.001<0.01), the other two groups had no significant difference. Comparison between groups, mild moxibustion group of patients than in the other two groups of patients with localized temperature increases, with significant difference (calcium group P=001, P=0.014compared with traditional Chinese Medicine), calcium group and the Chinese medicine group had no significant difference(P=0.389>0.05). Clinical effect of Chinese medicine determination results:
Clinical effect of mild moxibustion group accounted for31%, the total efficiency of86.2%. Chinese patent medicine group was33%, the total efficiency of86.7%, Mild moxibustion group and the traditional Chinese medicine curative effect had no significant difference, But were significantly better than the calcium group (P=0.007<0.01).
Determination of bone mineral density BMD results:the group after treatment, There were no significant differences.
Bone turnover markers determination results:The three groups before treatment comparison, each index showed no significant differences, with comparable (P>0.05), BGP group, Chinese medicine group and mild moxibustion group were significantly different(P=0<0.01), calcium group had no significant difference. BGP comparison between groups, mild moxibustion group than the calcium group increased significantly(P=0.004<0.01),a proprietary Chinese medicine group was significantly (P=0.075>0.05). BALP group, calcium groups before and after treatment was not significantly different,proprietary Chinese medicine group BALP increased (P=0.001<0.01), Mild moxibustion increased amplitude slightly larger (P=0<0.01).Between group and calcium compared, there are some differences(P<0.01). Chinese medicine and moxibustion group significantly increased compared to the value have no significant difference,both in the normal range(P=0.306).Three groups of TRACP5b decreased calcium groups before and after treatment, no differences, Chinese medicine and moxibustion group before and after treatment are compared, have significant difference (P<0.01), the three group after treatment, calcium group and there are significant differences between Chinese medicine group(P=0.005<0.01), and mild moxibustion group comparison difference(P=0.013<0.05), Chinese medicine group and mild moxibustion groups have not obvious difference. OPG group compared esultst:there were significant differences of proprietary Chinese medicine group, mild moxibustion has significant difference. But after treatment were compared between groups, mild moxibustion group and calcium group, have a certain degree of down(P=0.044<0.05), Chinese medicine group and calcium group differences(P=0.046<0.05).The three groups before and after treatment and compared between groups, serum calcium, phosphorus levels have no significant difference.
2Experimental studies have shown, the blank control component of bone cell apoptosis rate and cell apoptosis of mean lower than the other three groups, moxibustion serum composition of bone cell apoptosis, apoptosis and apoptosis induced by serum mean group and the comparison group, there are significant differences (P<0.05), serum controls and apoptosis induced by group comparison no significant difference(P>0.05). Three groups in the24hours of osteoblast proliferation od no difference (P>0.05), At48hours after each OD570obviously increased, The proliferation of moxibustion serum group greatly, and the blank control group, and serum in comparison to the control group, there were significant differences (P<0.05), Serum control group compared with the control group no significant difference(P>0.05). In different periods, the blank control group and control group the OD value of serum were increased, but there is no obvious difference in comparison within groups (P>0.05), moxibustion serum groups in different time slots within group comparisons, osteoblast OD570value were significantly increased.
Conclusion
1Mild moxibustion can obviously improve the kidney yang deficiency in postmenopausal osteoporosis patients clinical symptoms, relief of pain in osteoporosis, and is superior to other treatment group.
2Mild moxibustion can improve of osteoporosis with lumbar pain around the site and the infrared skin temperature value, effectively improve the kidney yang deficiency syndrome.
3Mild moxibustion can improve bone formation related indexes, decreased bone resorption related indicators, and bone turnover the kidney yang deficiency in postmenopausal osteoporosis patients.
4Moxibustion serum can promote the proliferation of osteoblasts, can reduce the TNF alpha induced apoptosis of osteoblastic cells number.
1通过随机设计的临床研究,观察温和灸对肾阳虚型绝经后骨质疏松症骨转换指标、临床骨痛及肾阳虚证候的影响,探讨其防治骨质疏松症临床效果及作用机制。
2通过实验研究来检测艾灸血清对骨质疏松症成骨细胞增殖率及凋亡情况,从细胞分子水平探讨其治疗骨质疏松症的作用机理。
方法：
1临床实验：运用温和灸疗法治疗肾阳虚型绝经后骨质疏松症,共入选研究病例90例,随机分为三组,每组各30例,研究结束后剔除不符合研究要求及脱落病例,共纳入统计病例87例,分别为：钙剂组28例,中成药组30例,温和灸组29例。钙剂组患者予以口服钙尔奇碳酸钙D3片,1片/次,1次/日。中成药组患者在钙剂组的治疗基础上加服仙灵骨葆胶囊,每次3粒,每日两次,温和灸组在钙剂组的治疗基础上循经取穴行温和灸疗法,隔日一次,取穴为3个主穴+3个配穴,主穴如下：脾俞、胃俞、肾俞。配穴选用命门、腰阳关、至阳。三组均连续治疗三个月,观察治疗前后肾阳虚证侯的变化及临床骨痛改善情况、骨密度、体表红外热图皮温的改变,并按中医临床疗效评定标准评价其疗效,空腹抽血检测治疗前后患者的骨形成相关指标：血清骨钙素(BGP)、血清骨碱性磷酸酶(BALP)。骨吸收相关指标抗酒石酸酸性磷酸酶5b(TRACP-5b)、骨保护素(OPG)。骨矿化指标血钙(Ca)、血磷(P)。治疗前后各指标比较组内采用配对样本t检验,组间差异用方差分析,行LSD、SNK法进行统计分析。
2体外培养细胞实验：通过观察大鼠艾灸血清对成骨细胞增殖与凋亡的影响,来探讨温和灸治疗骨质疏松症的细胞生物学机理。取10只出生24小时的新生SD大鼠无菌取颅盖顶骨,用单纯胶原酶消化法行成骨细胞培养,制成DMEM培养液重悬细胞,吹打均匀后接种到多个37℃、5%CO2饱和湿度的培养瓶中进行培养,进行成骨细胞HE染色观察及ALP染色鉴定,取二代细胞进行实验。将6月龄SD雌性大鼠随机分成2组：艾灸血清组、空白血清组,每组10只,艾灸血清组经用陈艾绒制成的艾条在大鼠背俞穴(脾俞、胃俞、肾俞、命门、腰阳关、至阳)行温和灸法,每天一次,每穴10分钟,连续21天,空白血清组大鼠除不作艾灸治疗外,余处理同艾灸血清组。制备艾灸血清和空白血清,同组血清混合后过滤除菌,56℃、30分钟水浴灭活,无菌冻存管分装、标记后-30℃冻存备用。取艾灸血清加入DMEM培养基中,制成含10%艾灸血清的培养液,同样取空白血清加入DMEM培养基中,制成含10%空白血清的培养液。将培养液分为空白对照组(含10%FBS、DMEM)、血清对照组(含10%空白血清、DMEM)和艾灸血清组(含10%艾灸血清、DMEM)三组进行培养,分别在24小时、48小时培养结束后,用MTT法检测成骨细胞增殖活性。按不同培养液条件分为空白对照组(含DMEM、10%FBS)、凋亡诱导组(DMEM.10%FBS、40ng/mlTNF-α),血清对照组(DMEM、10%空白血清、40ng/mlTNF-α)和艾灸血清组(DMEM、10%艾灸血清、40ng/mlTNF-α)四组,继续二代细胞培养,培养在48小时后完成,做HE、DAPI荧光染色,通过荧光倒置显微镜下检测成骨细胞凋亡情况。
结果：
1临床研究表明
肾阳虚证候积分测定结果：
治疗前后比较,钙剂组肾阳虚证候总积分比较无明显差异(P=0.676>0.05),中成药组畏寒肢冷证候积分无明显差异(P=0.083>0.05),余指标均有明显差异(P<0.01),其中以夜尿频多及疲乏无力证候改变为明显(P=0.001及P=0.003),温和灸组以畏寒肢冷、大便溏薄积分降低为明显(P=0.003及P=0.001),余证候积分P<0.05。治疗后组间方差分析两两比较,中成药组、温和灸与钙剂组在腰背疼痛及肾阳虚总积分改善方面有明显差异(P<0.05),温和灸与中成药组比较仅畏寒肢冷证候指标有显著差异(P=0.002<0.01),余证候指标相比较无明显差异(P>0.05)。
临床VAS测定结果：
治疗前后比较,钙剂组对于患者主观腰背疼痛症状无好转,VAS积分无明显改变,而中成药组及温和灸组均有明显好转(P=0.000<0.01)。治疗后三组组间比较,钙剂组VAS积分变化较小,中成药组与温和灸组相比,VAS积分下降幅度较大(P=0.015<0.05)。
红外热像皮温值测定结果：
结果显示,各组治疗前比较局部温度无明显差异,组内治疗前后比较,温和灸组局部温度明显升高(P=0.001<0.01),其他两组无明显差异。组间比较,温和灸组患者较其他两组患者局部温度增高,具有显著差异性(与钙剂组比较P=001,与中成药组比较P=0.014),钙剂组与中成药组无明显差异(P=0.389>0.05)。
中医临床疗效测定结果：
温和灸组临床显效占31.0%,总有效率86.2%。中成药组显效占33%,总有效率86.7%,温和灸组和中成药组疗效无明显差异,但均明显优于钙剂组(P=0.007<0.01)。
骨密度测定结果：骨密度各组间治疗后比较,均无显著差异。
骨转换指标的测定结果：
三组治疗前比较,各指标无明显差异,具有可比性(P>0.05),BGP组内比较,中药组及温和灸组有显著差异(P=0.000<0.01),钙剂组无明显差异。BGP组间比较,温和灸组较钙剂组显著增加(P=0.004<0.01),较中成药组明显无明显改变(P=0.075>0.05)。
BALP组内比较,钙剂组治疗前后无明显差异,中成药组BALP有所增加(P=0.001<0.01),温和灸增高的幅度略大(P=0.000<0.01)。组间与钙剂组相比较,均存在一定的差异性(P<0.01>0.05),中成药组和温和灸组增高值相比较无明显差异,都在正常范围(P=0.306)。
三组TRACP5b均有下降,钙剂组治疗前后比较无差异,中成药组及温和灸治疗前后相比较,具有显著差异(P<0.01),三组治疗后比较,钙剂组与中成药组比较存在显著差异性(P=0.005<0.01),与温和灸组比较有差异(P=0.013<0.05),中成药组与温和灸组比较无明显差异(P=0.775>0.05)。
OPG组内比较,中成药组存在显著差异(P=0.001<0.01),温和灸存在显著差异(P=0.002<0.01)。但治疗后组间比较,温和灸组与钙剂组相比,有一定程度的下降(P=0.044<0.05),中成药组与钙剂组比较有差异(P=0.046<0.05)。
三组治疗前后及各组间比较,血清钙、磷水平无明显差异(P>0.05)。
2实验研究表明,空白对照组成骨细胞凋亡率及凋亡细胞均值较其他三组少(P=0.000),艾灸血清组成骨细胞凋亡率、凋亡细胞均值与凋亡诱导组及血清对照组比较,有明显差异(P<0.05),血清对照组与凋亡诱导组比较无明显差异(P>0.05)。三组在24小时时段成骨细胞增殖OD570值无明显差异(P>0.05),在48小时后各组OD570均有明显增加,艾灸血清组增殖幅度较大,与空白对照组及血清对照组比较,有显著差异(P<0.05),血清对照组与空白对照组比较无明显差异(P>0.05)。在不同时段比较,空白对照组和血清对照组OD570值均增加,但组内比较尚无明显差异(P>0.05),艾灸血清组不同时段组内比较,成骨细胞OD570值有明显增加(P<0.01)。
结论：
1温和灸能明显改善肾阳虚绝经后骨质疏松症患者临床症状,缓解骨质疏松症骨痛,并优于其他治疗组。
2温和灸可明显提高肾阳虚型骨质疏松症腰部疼痛部位及周围的红外热像皮温值,有效改善肾阳虚证候。
3温和灸可提高骨形成相关指标水平,降低骨吸收相关指标,降低肾阳虚型PMOP的骨转换。
4艾灸血清能促进成骨细胞增殖,可减少TNF-α诱导的成骨细胞凋亡数量。
Objective
1Through a randomized clinical study designs, to observe the effect of Bone turnover markers, Clinical pain and Kidney yang deficiency syndrome on postmenopausal osteoporosis. to analysis the prevention of osteoporosis clinical efficacy and mechanism of action.
2Through the experimental research to detect the effect of moxibustion serum on osteoporosis osteoblast proliferation and apoptosis, From the cellular and molecular level to investigate its role in the treatment of osteoporosis mechanism.
Methods
1Clinieal study:A total of90patients with postmenopausal osteoporosis in kidney yang deficiency were assigned, and randomly divided into3groups,30cases in each group, the end of the study does not meet the research requirements and elimination after shedding case, were included in the statistical case87examples, respectively:28cases in the Calcium agent group,30cases in the Proprietary Chinese medicine group and29cases in the mild moxibustion group. Patiets in the Calcium agent group were treated by1Calcium carbonate tablets D3once daily, Patiets in the the Proprietary Chinese medicine group were treated by3Xianlinggubao capsules twice daily and1Calcium carbonate tablets D3once daily. Patiets in the mild moxibustion group were treated by mild moxibustion on the The main points as Pishu point, WeiShu point, ShenShu point and acupoints as Mingmen acupoint acupoints, YaoYangGuan acupoint, ZhiYang acupoint Once every other day and1Calcium carbonate tablets D once daily. All the patients were treated for three months. To Observe the change of Kidney yang deficiency syndrome, Clinical pain, Bone mineral density and Body surface skin temperature of infrared thermograph. According to TCM clinic curative effect evaluation of its curative effect. Meanwhile to determinate patients with bone formation index such as Osteocalcin(BGP), serum bone alkaline phosphatase(BALP), bone resorption index such as tartrate-resistant acid phosphatase5b (TRACP-5b), osteoprotegerin (OPG),bone mineralization indicators serum calcium(Ca), phosphorus(P). Comparison of indexes before and after treatment in group was used with paired sample t test, the differences between groups was used with analysis of variance, LSD, SNK method for statistical analysis, with P<0.05was considered statistically significant criteria.
2In vitro experiment:Through the observation of moxibustion serum on rat osteoblast proliferation and apoptosis, on mild-warm moxibustion for treatment of osteoporosis in cell biological mechanism.10born only24hours of neonatal SD rat calvarial bone aseptic were taken. DMEM medium heavy suspension cells came from Using pure collagenase digestion method line of osteoblasts culture, after All culture osteoblasts were inoculated into a plurality of37℃,5%CO2saturated humidity flask uniformed by Wind and percussion. HE staining and ALP staining identification were Conducted, experiments were using of the two generation cell. June old female SD rats were randomly divided into2groups, Each group of10. The rats of moxibustion serum group were treated with gentle moxibustion by moxa cone made by old argy wormwood leaf in rat Back-shu points once a day, each of10minutes for21days, To preparated moxibustion serum and blank serum. The same group of serum after mixing, filtration,56degrees,30minutes bath inactivation aseptic packaging, freezing tube, mark-30℃of cryopreserved standby. Using moxibustion serum added in DMEM medium containing10%, made of moxibustion serum medium, also take blank control group rats serum made with10%serum controls medium. The culture fluid is divided into the blank control group (10%FBS, DMEM), Serum control group (including10%blank serum, DMEM) and moxibustion serum group (including10%moxibustion serum, DMEM) in three groups were cultured respectively, in24hours,48hours after the cultivation,Use MTT method to detect the activity of osteoblast proliferation. According to different culture conditions were divided into control group(DMEM,10%FBS), Apoptosis induced by group (DMEM,10%FBS,40ng/ml TNF alpha), The control group, serum (DMEM,10%blank serum,40ng/ml TNF alpha)and moxibustion serum group (DMEM,10%,40ng/ml TNF moxibustion serum alpha) in four groups, continue to the two generation in cell culture, culture at48hours after completion, do DAPI fluorescence staining, Through an inverted fluorescence microscope osteoblast apoptosis.
Result
1In clinical studies have shown as follows:
Kidney yang deficiency syndrome integral determination results:
Calcium group of kidney-yang deficiency syndrome total no difference (P=0.676>0.05), Chinese medicine group of aversion to cold syndrome scores showed no significant difference(P=0.083>0.05), More than indicators have obvious differences (P<0.01), with nocturia and fatigue without evidence of climate change (P=0.001and P=0.003), Mild moxibustion group with aversion to cold, thin integral stool pond is reduced to significantly(P=0.003andP=0.001), P<0.05points more than syndrome. After treatment between group variance analysis comparison of two two, Chinese medicine group, mild moxibustion group and calcium in low back pain and kidney yang deficiency total integral improvement have obvious difference(P<0.05), Mild moxibustion and medicine group comparison only aversion to cold syndrome indices are significantly different(P=0.002<0.01), Other syndromes indices compared with no significant difference (P>0.05). Clinical result of measurement of VAS:
Comparison before and after treatment, calcium group for low back pain patients with subjective symptoms do not improve, VAS integral has no obvious change, and Chinese patent medicine group and mild moxibustion group were improved significantly(P=0<0.01). Between group after treatment between the three groups, calcium group VAS integral small changes, Chinese medicine group and mild moxibustion group compared with the VAS integral, a larger decrease(P=0.015<0.05).
Infrared thermography of skin temperature measurement results:
The results showed, each group before treatment comparison of local temperature had no significant differences within the group, after treatment, mild moxibustion group of local temperature increased significantly (P=0.001<0.01), the other two groups had no significant difference. Comparison between groups, mild moxibustion group of patients than in the other two groups of patients with localized temperature increases, with significant difference (calcium group P=001, P=0.014compared with traditional Chinese Medicine), calcium group and the Chinese medicine group had no significant difference(P=0.389>0.05). Clinical effect of Chinese medicine determination results:
Clinical effect of mild moxibustion group accounted for31%, the total efficiency of86.2%. Chinese patent medicine group was33%, the total efficiency of86.7%, Mild moxibustion group and the traditional Chinese medicine curative effect had no significant difference, But were significantly better than the calcium group (P=0.007<0.01).
Determination of bone mineral density BMD results:the group after treatment, There were no significant differences.
Bone turnover markers determination results:The three groups before treatment comparison, each index showed no significant differences, with comparable (P>0.05), BGP group, Chinese medicine group and mild moxibustion group were significantly different(P=0<0.01), calcium group had no significant difference. BGP comparison between groups, mild moxibustion group than the calcium group increased significantly(P=0.004<0.01),a proprietary Chinese medicine group was significantly (P=0.075>0.05). BALP group, calcium groups before and after treatment was not significantly different,proprietary Chinese medicine group BALP increased (P=0.001<0.01), Mild moxibustion increased amplitude slightly larger (P=0<0.01).Between group and calcium compared, there are some differences(P<0.01). Chinese medicine and moxibustion group significantly increased compared to the value have no significant difference,both in the normal range(P=0.306).Three groups of TRACP5b decreased calcium groups before and after treatment, no differences, Chinese medicine and moxibustion group before and after treatment are compared, have significant difference (P<0.01), the three group after treatment, calcium group and there are significant differences between Chinese medicine group(P=0.005<0.01), and mild moxibustion group comparison difference(P=0.013<0.05), Chinese medicine group and mild moxibustion groups have not obvious difference. OPG group compared esultst:there were significant differences of proprietary Chinese medicine group, mild moxibustion has significant difference. But after treatment were compared between groups, mild moxibustion group and calcium group, have a certain degree of down(P=0.044<0.05), Chinese medicine group and calcium group differences(P=0.046<0.05).The three groups before and after treatment and compared between groups, serum calcium, phosphorus levels have no significant difference.
2Experimental studies have shown, the blank control component of bone cell apoptosis rate and cell apoptosis of mean lower than the other three groups, moxibustion serum composition of bone cell apoptosis, apoptosis and apoptosis induced by serum mean group and the comparison group, there are significant differences (P<0.05), serum controls and apoptosis induced by group comparison no significant difference(P>0.05). Three groups in the24hours of osteoblast proliferation od no difference (P>0.05), At48hours after each OD570obviously increased, The proliferation of moxibustion serum group greatly, and the blank control group, and serum in comparison to the control group, there were significant differences (P<0.05), Serum control group compared with the control group no significant difference(P>0.05). In different periods, the blank control group and control group the OD value of serum were increased, but there is no obvious difference in comparison within groups (P>0.05), moxibustion serum groups in different time slots within group comparisons, osteoblast OD570value were significantly increased.
Conclusion
1Mild moxibustion can obviously improve the kidney yang deficiency in postmenopausal osteoporosis patients clinical symptoms, relief of pain in osteoporosis, and is superior to other treatment group.
2Mild moxibustion can improve of osteoporosis with lumbar pain around the site and the infrared skin temperature value, effectively improve the kidney yang deficiency syndrome.
3Mild moxibustion can improve bone formation related indexes, decreased bone resorption related indicators, and bone turnover the kidney yang deficiency in postmenopausal osteoporosis patients.
4Moxibustion serum can promote the proliferation of osteoblasts, can reduce the TNF alpha induced apoptosis of osteoblastic cells number.
引文
[1]Christiansen C, Riis P. Consensus development conference. Prophylaxis and treatment of osteoporosis[J]. Nord Med.1991;106(5):145.
[2]Pierre D Delmas, John Curtis Stevenson. International Symposium on Osteoporosis and Consensus Development Conference[M]. New York:MSP International,1993,4:646-650.
[3]Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis:synopsis of a WHO report. WHO Study Group. Osteoporos Int[J]. 1994,4(6):368.
[4]United Nations. The Sex and age distributions of population.The 1994 revision of the United Nations global population estimates and projections[M], New York:1995.
[5]Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis[J].1994 World Health Ogran Tech Rep Ser,1994,843:1-129.
[6]徐苓.骨质疏松症[M].上海：上海科学技术出版社,2011,11：63.
[7]郭世绂,罗先正,邱贵兴.骨质疏松基础与临床[M].天津：天津科学技术出版社,2001：330
[8]中华医学会.临床诊疗指南·骨质疏松症和骨矿盐疾病分册[M].北京：人民卫生出版社,2006.12：3.
[9]中国人骨质疏松症建议诊断标准(第二稿)[J].中国骨质疏松杂志.2000,6(1)：1.
[10]廖二元.更新知识、规范诊疗—应对骨质疏松症的高患病率[J].药品评价,2012,9(7)：7.
[11]马俊岭,郭海英,阳晓东.骨质疏松症的流行病学概况[J].中国全科医学,2009,12(18)：1744-1746.
[12]胡军,张华,牟青.骨质疏松症的流行病学趋势与防治进展[J].临床荟萃.2011,26(8)：730.
[13]王久和,常虹.植物雌激素防治绝经后骨质疏松症的研究进展[J].内蒙古医学院学报,2010,32(4)：92.
[14]黄立,莉洪,文王,等.绝经后骨质疏松症的临床治疗进展[J].中国医药导报2011,8(18)：7.
[15]章时珍,汪煌,段斌斌,等.雌激素及其受体对骨质疏松症影响的研究进展[J].中国骨质疏松杂志,2011,17(05)：455.
[16]李万根,张彤.绝经后妇女骨密度与胰岛素、胰岛素样生长因子Ⅰ及瘦素的关系[J].中国临床康复,2004,8(24)：36-37.
[17]章秋.原发性骨质疏松症的病因和发病机制[J].安徽医学,2003,23(2)：2.
[18]李珂欣,闻成艳,兰丹.老年人骨质疏松症的病因及防治[J].中国临床康复,2002,6(7)：1058
[19]颜晓东,黄忠,朱敏嘉,等.绝经后妇女血清调钙激素水平与骨代谢关系探讨[J].中国骨质疏松杂志,2001,7(3)：207-209.
[20]赵荣,陶静.原发性骨质疏松症的病因学研究进展[J].云南中医学院学报,2007,30(2)： 67-70.
[21]马尊良,邢学农。甲状旁腺素治疗骨质疏松的新进展[J].国际老年医学杂志2010,31(6)：273.
[22]吴科锐.骨质疏松症的病因学研究进展[J].2011,17(5)：191.
[23]刘忠厚.骨矿与临床[M].北京：中国科学技术出版社,2006：641.
[24]刘辉文,邓小戈,廖二元.绝经后骨质疏松相关基因多态性的研究进展[J].国外医学妇产科学分册,2002,(6)：358-360.
[25]王新祥,张允岭,黄启福.对骨质疏松症中医主要病机和现代病因学的认识与探讨[J].中西医结合学报,2010,8(12)：1119.
[26]吴科锐.骨质疏松症的病因学研究进展[J].中外医疗,2011,30(17)：191.
[27]莫凤媚.女性原发性骨质疏松症的病因和检查方法[J].广西医学,2005,27(8)：1199.
[28]张摇楠,章摇秋,骨代谢.骨生化指标在骨质疏松症中的应用[J],安徽医药,2011,4,15(4)：401.
[29]梅敏.骨质疏松症治疗研究进展[J].吉林医学,2011,32(4)：749-750.
[30]黄相杰,毕晓英,姜红江.绝经后骨质疏松症治疗的研究进展[J].中国骨质疏松杂志,2010,16(8)：602.
[31]吴洁,刘忠厚.选择性雌激素受体调节剂在绝经后骨质疏松症治疗中作用的研究进展[J].中国骨质疏松杂志,2008,14(11)：830.
[32]方岩,范辉,王燕慧.钙剂,维生素D与骨质疏松症[J].中国骨质疏松杂志,2011,17(8)：723
[33]包丽华,林华,李永军,等.伊班膦酸钠和阿仑膦酸钠对绝经后骨质疏松的干预研究[J].中国骨质疏松杂杂志,2011,17(3)：232.
[34]连建强,降钙素治疗骨质疏松症的研究进展[J].医学综述,2011,17(12)：1860.
[35]许红霞,杨少辉,董华军.抗骨质疏松症的药物的研究进展[J],食品与药品：2011,13(01)：12.
[36]马中兴,高文杰,魏小堂.等.中医学对骨质疏松症病因病机的认识[J].中医研究,2012,25(1)：14.
[37]张学娅,许东云,张颖,等.从“肝肾同源”论探讨骨质疏松症病因病机及其治疗原则[J].辽宁中医杂志,2011,38(12)：2362.
[38]岳荣超,王鸿度.骨质疏松症病因病机探讨[J].山东中医杂志,2012,31(1)：3.
[39]刘锐,伍娟娟.从“骨络”探讨骨质疏松症的病因病机[J].中医研究,2010,13(1)：11.
[40]余清,苏宜香,王文蔚.大豆异黄酮对骨质疏松症动物模型骨代谢及形态学的影响[J].中华预防医学杂志,41(4)：299.
[41]吴以岭.络病学[M].北京：中国中医药出版社,2006：326-334.
[42]邵敏.骨质疏松症的中医治则探讨[J].新中医,2001,32(1)：15.
[43]刘海全,秦佳佳,赵玉林,等.中医药治疗原发性骨质疏松症现状与展望[J].时珍国医国药,2010,21(6)：1494.
[45]章凤兰.西医代谢调节与中医补肾疗法治疗绝经后骨质疏松症作用机制的相关性与差异[J].中国临床康复,2005,9(3)：223.
[46]刘红健,邓伟,吴国珍,等.温肾补阳法治疗原发性骨质疏松症的临床研究[J].中国康复医学杂志,2007年,22(11)：1028.
[47]寿依群,陈文君,李建华,等.传统针灸治疗骨质疏松症的研究进展[J].中国康复医学杂志,2004,19(6)：476.
[48]康轶鑫,于道全,刘忠厚.针灸治疗骨质疏松症的实验研究进展[J].中国骨质疏松杂志2011,17(1)：73.
[49]李国瑛,唐慧,童琴.针灸加桂枝茯苓汤加味治疗绝经后骨质疏松症的临床观察[J].中国骨质疏松杂志.2012,18(2)：169.
[50]蒙家辉,罗小珍,罗盛华,等.针灸结合蜡疗治疗骨质疏松症腰背痛的临床疗效研究[J].中国全科医学,2010,13(7)：2156.
[51]陈文治,冯文轩.针灸治疗骨质疏松症的研究进展[J].陕西中医,2010,31(8)：1093.
[52]康轶鑫,王道全,刘忠厚.针灸治疗骨质疏松症的临床研究进展[J].中国骨质疏松症杂志,2010,16(9)：708.
[53]王俊伏.艾条温和灸的临证运用[J].河南中医,2004.24(7)：67.
[54]栗冬,张妤,陈以国,等.温和灸对痛经大鼠血清CD3、CD4、CD8影响的实验研究[J].山西中医,2012,28(3)：49.
[55]陈波,熊芳丽,方志聪,等.温和灸对中老年膝骨性关节炎患者生活能力与生活质量的影响[J].山东医药,2010,50(32)：43.
[56]谭琳蓥,赵天平,国兰琴,等.温和灸对自然衰老模型大鼠肝组织Rb、P53、Bcl-2、PKC表达的影响[J].环球中医药,2011,4(6)：406-412.
[57]陈日新,康明非.腧穴热敏化艾灸新疗法[M].北京：人民卫生出版社,2006：26.
[58]丁光宏,沈雪勇,褚君浩,等.中医灸与人体穴位红外辐射光谱特性研究[J].中国生物医学工程学报,2002,21(4)：356-360.
[59]洪文学,蔡建红,景军,等.传统中医艾灸疗法的热辐射光谱特性的研究[J].生物医学工程研究,2003,22(4)：27-30.
[60]周楣声.灸绳[M].青岛：青岛出版社,1998：208.
[61]中华医学会.临床诊疗指南·骨质疏松症和骨矿盐疾病分册[M].北京：人民卫生出版社.2008.5：1-7.
[62]杨露晨,魏铮,吴巧凤,等.艾灸血清对实验性RA滑膜细胞增殖及细胞周期的影响[J].成都中医药大学学报.2008,3(2)：33.
[63]孙德利,陈汉平.“针灸血清”的研究方法及意义[J].浙江中医学院学报,1999,23：59.
[64]陈汉平,裴建.关于“针灸血清”方法的研究和应用[J].上海针灸杂志,1998,1(17)：1.
[65]黄筠,魏莉,熊一向.艾灸血清对人肺腺癌细胞株A549体外生长的影响[J].中国中医基础医 学杂志,2010,16(12)：1160.
[66]Chen Yunfei, Zhao Cuiying, Lv Qiyong. Experimental Research on the Anti-tumor Effect of vMoxibustion Serum, J. Acupunct. Tuina. Sci[J].2011,9(6):336-339.
[67]邓春雷,殷克敬.实验针灸学[M].北京：人民卫生出版社,1998,3：147.
[68]周次利,张淑静,张丹.针灸血清研究现状与思考[J].中华中医药学刊,2011,29(3)：484.
[69]马晓芫,赵粹英,李祖剑,等艾灸血清体外对小鼠EL-4淋巴瘤细胞作用的实验研究[J].中医药学刊,2003,21(11)：1949.
[70]陈云匕,赵粹英,陈汉平.“艾灸血清”对肿瘤浸润淋巴细胞增殖和表型的影响[J].中国针灸,2002,22(4)：221.
[71]张建斌,王玲玲,胡玲,等.艾灸温通作用的理论探讨[J].中国针灸,2011,,31(1)：51.
[72]刘忠厚等.骨质疏松症的诊断和筛选[J].中国老年学杂志.1995;15(1)：53-56.
[73]卞兆祥,提高中草药随机对照试验的质量Ⅱ对照组设计[J].中西医结合学报,2006,4(2)：130-136.
[74]何元诚,张文诚.仙灵骨葆与骨质疏松症[J].浙江中西医结合杂志,2009,19(2)：115.
[75]刘欣,宋英杰,刘子良.仙灵骨葆胶囊治疗骨质疏松症50例疗效观察[J].中国医疗前沿,2008,23(3)：55.
[76]王旭凯,王英,杨有庚.仙灵骨葆胶囊治疗绝经后妇女骨质疏松症的临床疗效观察[J].中国妇幼保健.2009,12(13)：461.
[77]倪力刚,王伟,李春雯,等.仙灵骨葆胶囊对骨质疏松性髋部骨折的研究近况[J].中国骨质疏松杂志2011,17(11)：1014.
[78]刘肖瑜,周肃陵,王正.红外热图技术与腰椎间盘突出症中医证型相关性研究[J].中国中医骨伤科杂志,2010,16(5)：10.
[79]谷华,孙丽斌,于畅,等.红外热图温度与肿瘤中医证型的关系[J].临床军医杂志,2009,37(3)：389.
[80]丁晶,周志尊,李帅三,医用红外线热成像技术的物理学原理探析[J].中国医疗设备.2010(7)：66.
[81]刘作勤.DSA特殊功能的临床应用Ⅱ[J].医疗保健器具,2007(12)：23-24.
[82]廖怀章,孙江波,刘绪银援骨质疏松症中医定性证候与骨密度水平的相关性研究[J].湖南中医杂志,2010,26(5)：51-53.
[83]向青,苏楠,刘忠厚.第二代骨吸收生化标志物血清抗酒石酸酸性磷酸酶5b的临床研究[J].中国骨质疏松杂志,2002,8(4)：331.
[84]曾芳馨,熊中云.抗酒石酸酸性磷酸酶与骨代谢[J].华两医学,2005,20(3)：545.
[85]Nakasato YR, Janckila AJ, Halleen JM, et al. Clinical significance of immunoassays, for type 5 tartrate-resistant acid phosphatase. Clin Chem[J],1999,445:2150-2157.
[86]Hallen JM, Alatalo SL, Ivaska KK, et al. Serum tartrate-resistant acidphosphat ase 5b is a useful marker for monitoring alendronate therapy. J Bone Miner Res[J],2001, 16(suppl):S534.
[87]张摇楠,章摇秋.骨代谢生化指标在骨质疏松症中的应用[J].安徽医学.2005,15(4)：401.
[88]程婉,许兵,应航,等.抗骨质疏松中药对成骨细胞作用的研究进展[J].中医正骨,2012,24(2)：65.
[89]陈云飞,赵粹英,陈汉平.小鼠艾灸血清诱导肿瘤细胞凋亡的实验研究[J].针刺研究,2000,25(1)：38.
[90]林伟眷,梁婉仪,郑黎勤.艾灸与雌激素替代治疗绝经后骨质疏松症的疗效比较[J],中医药导报,2006,12(7)：63-65.
[91]李瑞午,张金铃,郭荧,等.针灸血清对大脑皮层细胞内钙离子的影响初探-针灸体液机理的研究[J].中国针灸,2005,25(5)：351.
[92]仇士东,温学森。从系统生物学角度研究肾虚证概况[J].中医杂志2011,52(6)：528.
[93]徐敏,刘保新,黄承军.绝经后骨质疏松症的穴位治疗进展[J].浙江中医药大学学报2011,35(2)：301.
[94]曾涛.浅析针灸临床取穴配穴原则及常见病的治疗[J].中国实用医药.2007,2(20)：78.
[95]潘小燕,王鸿度.针灸治疗原发性骨质疏松症的取穴规律[J].四川中医,2011,29(3)：55.
[2]Pierre D Delmas, John Curtis Stevenson. International Symposium on Osteoporosis and Consensus Development Conference[M]. New York:MSP International,1993,4:646-650.
[3]Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis:synopsis of a WHO report. WHO Study Group. Osteoporos Int[J]. 1994,4(6):368.
[4]United Nations. The Sex and age distributions of population.The 1994 revision of the United Nations global population estimates and projections[M], New York:1995.
[5]Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis[J].1994 World Health Ogran Tech Rep Ser,1994,843:1-129.
[6]徐苓.骨质疏松症[M].上海：上海科学技术出版社,2011,11：63.
[7]郭世绂,罗先正,邱贵兴.骨质疏松基础与临床[M].天津：天津科学技术出版社,2001：330
[8]中华医学会.临床诊疗指南·骨质疏松症和骨矿盐疾病分册[M].北京：人民卫生出版社,2006.12：3.
[9]中国人骨质疏松症建议诊断标准(第二稿)[J].中国骨质疏松杂志.2000,6(1)：1.
[10]廖二元.更新知识、规范诊疗—应对骨质疏松症的高患病率[J].药品评价,2012,9(7)：7.
[11]马俊岭,郭海英,阳晓东.骨质疏松症的流行病学概况[J].中国全科医学,2009,12(18)：1744-1746.
[12]胡军,张华,牟青.骨质疏松症的流行病学趋势与防治进展[J].临床荟萃.2011,26(8)：730.
[13]王久和,常虹.植物雌激素防治绝经后骨质疏松症的研究进展[J].内蒙古医学院学报,2010,32(4)：92.
[14]黄立,莉洪,文王,等.绝经后骨质疏松症的临床治疗进展[J].中国医药导报2011,8(18)：7.
[15]章时珍,汪煌,段斌斌,等.雌激素及其受体对骨质疏松症影响的研究进展[J].中国骨质疏松杂志,2011,17(05)：455.
[16]李万根,张彤.绝经后妇女骨密度与胰岛素、胰岛素样生长因子Ⅰ及瘦素的关系[J].中国临床康复,2004,8(24)：36-37.
[17]章秋.原发性骨质疏松症的病因和发病机制[J].安徽医学,2003,23(2)：2.
[18]李珂欣,闻成艳,兰丹.老年人骨质疏松症的病因及防治[J].中国临床康复,2002,6(7)：1058
[19]颜晓东,黄忠,朱敏嘉,等.绝经后妇女血清调钙激素水平与骨代谢关系探讨[J].中国骨质疏松杂志,2001,7(3)：207-209.
[20]赵荣,陶静.原发性骨质疏松症的病因学研究进展[J].云南中医学院学报,2007,30(2)： 67-70.
[21]马尊良,邢学农。甲状旁腺素治疗骨质疏松的新进展[J].国际老年医学杂志2010,31(6)：273.
[22]吴科锐.骨质疏松症的病因学研究进展[J].2011,17(5)：191.
[23]刘忠厚.骨矿与临床[M].北京：中国科学技术出版社,2006：641.
[24]刘辉文,邓小戈,廖二元.绝经后骨质疏松相关基因多态性的研究进展[J].国外医学妇产科学分册,2002,(6)：358-360.
[25]王新祥,张允岭,黄启福.对骨质疏松症中医主要病机和现代病因学的认识与探讨[J].中西医结合学报,2010,8(12)：1119.
[26]吴科锐.骨质疏松症的病因学研究进展[J].中外医疗,2011,30(17)：191.
[27]莫凤媚.女性原发性骨质疏松症的病因和检查方法[J].广西医学,2005,27(8)：1199.
[28]张摇楠,章摇秋,骨代谢.骨生化指标在骨质疏松症中的应用[J],安徽医药,2011,4,15(4)：401.
[29]梅敏.骨质疏松症治疗研究进展[J].吉林医学,2011,32(4)：749-750.
[30]黄相杰,毕晓英,姜红江.绝经后骨质疏松症治疗的研究进展[J].中国骨质疏松杂志,2010,16(8)：602.
[31]吴洁,刘忠厚.选择性雌激素受体调节剂在绝经后骨质疏松症治疗中作用的研究进展[J].中国骨质疏松杂志,2008,14(11)：830.
[32]方岩,范辉,王燕慧.钙剂,维生素D与骨质疏松症[J].中国骨质疏松杂志,2011,17(8)：723
[33]包丽华,林华,李永军,等.伊班膦酸钠和阿仑膦酸钠对绝经后骨质疏松的干预研究[J].中国骨质疏松杂杂志,2011,17(3)：232.
[34]连建强,降钙素治疗骨质疏松症的研究进展[J].医学综述,2011,17(12)：1860.
[35]许红霞,杨少辉,董华军.抗骨质疏松症的药物的研究进展[J],食品与药品：2011,13(01)：12.
[36]马中兴,高文杰,魏小堂.等.中医学对骨质疏松症病因病机的认识[J].中医研究,2012,25(1)：14.
[37]张学娅,许东云,张颖,等.从“肝肾同源”论探讨骨质疏松症病因病机及其治疗原则[J].辽宁中医杂志,2011,38(12)：2362.
[38]岳荣超,王鸿度.骨质疏松症病因病机探讨[J].山东中医杂志,2012,31(1)：3.
[39]刘锐,伍娟娟.从“骨络”探讨骨质疏松症的病因病机[J].中医研究,2010,13(1)：11.
[40]余清,苏宜香,王文蔚.大豆异黄酮对骨质疏松症动物模型骨代谢及形态学的影响[J].中华预防医学杂志,41(4)：299.
[41]吴以岭.络病学[M].北京：中国中医药出版社,2006：326-334.
[42]邵敏.骨质疏松症的中医治则探讨[J].新中医,2001,32(1)：15.
[43]刘海全,秦佳佳,赵玉林,等.中医药治疗原发性骨质疏松症现状与展望[J].时珍国医国药,2010,21(6)：1494.
[45]章凤兰.西医代谢调节与中医补肾疗法治疗绝经后骨质疏松症作用机制的相关性与差异[J].中国临床康复,2005,9(3)：223.
[46]刘红健,邓伟,吴国珍,等.温肾补阳法治疗原发性骨质疏松症的临床研究[J].中国康复医学杂志,2007年,22(11)：1028.
[47]寿依群,陈文君,李建华,等.传统针灸治疗骨质疏松症的研究进展[J].中国康复医学杂志,2004,19(6)：476.
[48]康轶鑫,于道全,刘忠厚.针灸治疗骨质疏松症的实验研究进展[J].中国骨质疏松杂志2011,17(1)：73.
[49]李国瑛,唐慧,童琴.针灸加桂枝茯苓汤加味治疗绝经后骨质疏松症的临床观察[J].中国骨质疏松杂志.2012,18(2)：169.
[50]蒙家辉,罗小珍,罗盛华,等.针灸结合蜡疗治疗骨质疏松症腰背痛的临床疗效研究[J].中国全科医学,2010,13(7)：2156.
[51]陈文治,冯文轩.针灸治疗骨质疏松症的研究进展[J].陕西中医,2010,31(8)：1093.
[52]康轶鑫,王道全,刘忠厚.针灸治疗骨质疏松症的临床研究进展[J].中国骨质疏松症杂志,2010,16(9)：708.
[53]王俊伏.艾条温和灸的临证运用[J].河南中医,2004.24(7)：67.
[54]栗冬,张妤,陈以国,等.温和灸对痛经大鼠血清CD3、CD4、CD8影响的实验研究[J].山西中医,2012,28(3)：49.
[55]陈波,熊芳丽,方志聪,等.温和灸对中老年膝骨性关节炎患者生活能力与生活质量的影响[J].山东医药,2010,50(32)：43.
[56]谭琳蓥,赵天平,国兰琴,等.温和灸对自然衰老模型大鼠肝组织Rb、P53、Bcl-2、PKC表达的影响[J].环球中医药,2011,4(6)：406-412.
[57]陈日新,康明非.腧穴热敏化艾灸新疗法[M].北京：人民卫生出版社,2006：26.
[58]丁光宏,沈雪勇,褚君浩,等.中医灸与人体穴位红外辐射光谱特性研究[J].中国生物医学工程学报,2002,21(4)：356-360.
[59]洪文学,蔡建红,景军,等.传统中医艾灸疗法的热辐射光谱特性的研究[J].生物医学工程研究,2003,22(4)：27-30.
[60]周楣声.灸绳[M].青岛：青岛出版社,1998：208.
[61]中华医学会.临床诊疗指南·骨质疏松症和骨矿盐疾病分册[M].北京：人民卫生出版社.2008.5：1-7.
[62]杨露晨,魏铮,吴巧凤,等.艾灸血清对实验性RA滑膜细胞增殖及细胞周期的影响[J].成都中医药大学学报.2008,3(2)：33.
[63]孙德利,陈汉平.“针灸血清”的研究方法及意义[J].浙江中医学院学报,1999,23：59.
[64]陈汉平,裴建.关于“针灸血清”方法的研究和应用[J].上海针灸杂志,1998,1(17)：1.
[65]黄筠,魏莉,熊一向.艾灸血清对人肺腺癌细胞株A549体外生长的影响[J].中国中医基础医 学杂志,2010,16(12)：1160.
[66]Chen Yunfei, Zhao Cuiying, Lv Qiyong. Experimental Research on the Anti-tumor Effect of vMoxibustion Serum, J. Acupunct. Tuina. Sci[J].2011,9(6):336-339.
[67]邓春雷,殷克敬.实验针灸学[M].北京：人民卫生出版社,1998,3：147.
[68]周次利,张淑静,张丹.针灸血清研究现状与思考[J].中华中医药学刊,2011,29(3)：484.
[69]马晓芫,赵粹英,李祖剑,等艾灸血清体外对小鼠EL-4淋巴瘤细胞作用的实验研究[J].中医药学刊,2003,21(11)：1949.
[70]陈云匕,赵粹英,陈汉平.“艾灸血清”对肿瘤浸润淋巴细胞增殖和表型的影响[J].中国针灸,2002,22(4)：221.
[71]张建斌,王玲玲,胡玲,等.艾灸温通作用的理论探讨[J].中国针灸,2011,,31(1)：51.
[72]刘忠厚等.骨质疏松症的诊断和筛选[J].中国老年学杂志.1995;15(1)：53-56.
[73]卞兆祥,提高中草药随机对照试验的质量Ⅱ对照组设计[J].中西医结合学报,2006,4(2)：130-136.
[74]何元诚,张文诚.仙灵骨葆与骨质疏松症[J].浙江中西医结合杂志,2009,19(2)：115.
[75]刘欣,宋英杰,刘子良.仙灵骨葆胶囊治疗骨质疏松症50例疗效观察[J].中国医疗前沿,2008,23(3)：55.
[76]王旭凯,王英,杨有庚.仙灵骨葆胶囊治疗绝经后妇女骨质疏松症的临床疗效观察[J].中国妇幼保健.2009,12(13)：461.
[77]倪力刚,王伟,李春雯,等.仙灵骨葆胶囊对骨质疏松性髋部骨折的研究近况[J].中国骨质疏松杂志2011,17(11)：1014.
[78]刘肖瑜,周肃陵,王正.红外热图技术与腰椎间盘突出症中医证型相关性研究[J].中国中医骨伤科杂志,2010,16(5)：10.
[79]谷华,孙丽斌,于畅,等.红外热图温度与肿瘤中医证型的关系[J].临床军医杂志,2009,37(3)：389.
[80]丁晶,周志尊,李帅三,医用红外线热成像技术的物理学原理探析[J].中国医疗设备.2010(7)：66.
[81]刘作勤.DSA特殊功能的临床应用Ⅱ[J].医疗保健器具,2007(12)：23-24.
[82]廖怀章,孙江波,刘绪银援骨质疏松症中医定性证候与骨密度水平的相关性研究[J].湖南中医杂志,2010,26(5)：51-53.
[83]向青,苏楠,刘忠厚.第二代骨吸收生化标志物血清抗酒石酸酸性磷酸酶5b的临床研究[J].中国骨质疏松杂志,2002,8(4)：331.
[84]曾芳馨,熊中云.抗酒石酸酸性磷酸酶与骨代谢[J].华两医学,2005,20(3)：545.
[85]Nakasato YR, Janckila AJ, Halleen JM, et al. Clinical significance of immunoassays, for type 5 tartrate-resistant acid phosphatase. Clin Chem[J],1999,445:2150-2157.
[86]Hallen JM, Alatalo SL, Ivaska KK, et al. Serum tartrate-resistant acidphosphat ase 5b is a useful marker for monitoring alendronate therapy. J Bone Miner Res[J],2001, 16(suppl):S534.
[87]张摇楠,章摇秋.骨代谢生化指标在骨质疏松症中的应用[J].安徽医学.2005,15(4)：401.
[88]程婉,许兵,应航,等.抗骨质疏松中药对成骨细胞作用的研究进展[J].中医正骨,2012,24(2)：65.
[89]陈云飞,赵粹英,陈汉平.小鼠艾灸血清诱导肿瘤细胞凋亡的实验研究[J].针刺研究,2000,25(1)：38.
[90]林伟眷,梁婉仪,郑黎勤.艾灸与雌激素替代治疗绝经后骨质疏松症的疗效比较[J],中医药导报,2006,12(7)：63-65.
[91]李瑞午,张金铃,郭荧,等.针灸血清对大脑皮层细胞内钙离子的影响初探-针灸体液机理的研究[J].中国针灸,2005,25(5)：351.
[92]仇士东,温学森。从系统生物学角度研究肾虚证概况[J].中医杂志2011,52(6)：528.
[93]徐敏,刘保新,黄承军.绝经后骨质疏松症的穴位治疗进展[J].浙江中医药大学学报2011,35(2)：301.
[94]曾涛.浅析针灸临床取穴配穴原则及常见病的治疗[J].中国实用医药.2007,2(20)：78.
[95]潘小燕,王鸿度.针灸治疗原发性骨质疏松症的取穴规律[J].四川中医,2011,29(3)：55.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |